JAG1 and prostate carcinoma: Both gal-3 and JAG1 are overexpressed in several malignancies such as prostate cancer, breast cancer, glioma and head and neck cancers and are largely appreciated as potential targets for cancer therapy, including antiangiogenic therapy [45, 46].